{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T11:42:58Z","timestamp":1788090178264,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05811-x","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T01:11:16Z","timestamp":1787188276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world safety profile of eravacycline compared with tigecycline, minocycline, and meropenem: a comparative pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1007","author":[{"given":"Yan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6316-6361","authenticated-orcid":false,"given":"Jianfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"5811_CR1","doi-asserted-by":"publisher","first-page":"1670648","DOI":"10.3389\/fpain.2025.1670648","volume":"6","author":"AI Alzarea","year":"2025","unstructured":"Alzarea AI, Ishaqui AA, Maqsood MB, Alanazi AS, Alsaidan AA, Mallhi TH, Kumar N, Orayj KM, Alshahran SM, Alhassan HH, Alzarea SI, Alsaidan OA (2025) Drug-induced headache reports: a comprehensive disproportionality and time-to-onset pharmacovigilance study using the FAERS database (2018\u20132024). Front Pain Res (Lausanne) 6:1670648. https:\/\/doi.org\/10.3389\/fpain.2025.1670648","journal-title":"Front Pain Res (Lausanne)"},{"key":"5811_CR2","doi-asserted-by":"publisher","first-page":"1645114","DOI":"10.3389\/fphar.2025.1645114","volume":"16","author":"Y An","year":"2025","unstructured":"An Y, Zheng Y, Jiang Z, Meng M, Yin J, An Y (2025) Identification of potential drug-induced neuralgia signals through disproportionality analysis of the FAERS database. Front Pharmacol 16:1645114. https:\/\/doi.org\/10.3389\/fphar.2025.1645114","journal-title":"Front Pharmacol"},{"key":"5811_CR3","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.2147\/IDR.S529016","volume":"18","author":"J Chen","year":"2025","unstructured":"Chen J, Qian X, Yue B, Lin H, Ding S, Chen J, Huang M (2025) Eravacycline treatment for carbapenem-resistant Acinetobacter baumannii in lung transplant recipients: a real-world retrospective study. Infect Drug Resist 18:4125\u20134139. https:\/\/doi.org\/10.2147\/IDR.S529016. (eCollection 2025. PMID: 40851759.)","journal-title":"Infect Drug Resist"},{"issue":"4","key":"5811_CR4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","volume":"71","author":"CL Daley","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, B\u00f6ttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL (2020Aug 14) Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Clin Infect Dis 71(4):e1\u2013e36. https:\/\/doi.org\/10.1093\/cid\/ciaa241. (PMID: 32628747)","journal-title":"Clin Infect Dis"},{"issue":"178","key":"5811_CR5","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0038-2025","volume":"34","author":"CL Daley","year":"2025","unstructured":"Daley CL, Flume PA, van Ingen J, Khare R, Mingora CM, Nguyen MH, Winthrop KL, Zha BS (2025) A systematic review of tetracyclines for nontuberculous mycobacteria: focus on rapidly growing mycobacteria. Eur Respir Rev 34(178):250038. https:\/\/doi.org\/10.1183\/16000617.0038-2025. (PMID: 41193247)","journal-title":"Eur Respir Rev"},{"issue":"2","key":"5811_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W DuMouchel","year":"1999","unstructured":"DuMouchel W (1999) Bayesian data mining in large frequency tables, with an application to the FDA Spontaneous Reporting System. Am Stat 53(2):177\u2013190. https:\/\/doi.org\/10.1080\/00031305.1999.10474456","journal-title":"Am Stat"},{"issue":"12","key":"5811_CR7","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3390\/pathogens14121214","volume":"14","author":"ME Falagas","year":"2025","unstructured":"Falagas ME, Romanos LT, Kontogiannis DS, Filippou C, Karageorgopoulos DE (2025) Resistance of gram-negative bacteria to eravacycline: a systematic review of data from in vitro studies. Pathogens 14(12):1214. https:\/\/doi.org\/10.3390\/pathogens14121214. (PMID: 41471170)","journal-title":"Pathogens"},{"issue":"10459","key":"5811_CR8","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"GBD","year":"2021","unstructured":"GBD (2021) Antimicrobial Resistance Collaborators (2024) Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050. Lancet 404(10459):1199\u20131226. https:\/\/doi.org\/10.1016\/S0140-6736(24)01867-1","journal-title":"Lancet"},{"issue":"6","key":"5811_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2026.107795","volume":"67","author":"Y Hou","year":"2026","unstructured":"Hou Y, Zhang L, Li H, Zhong L, Zhang H, Tang T, Zheng X, Zhou R, Lv S, Que Q, Tan B, Chen L, Hsu Y, Hu H, Shen J, Yue R, Chen K, Di W, Guo L, Chen L, Yu H, Huang X, Huang X, Pan C, Yang H, Pan L (2026) Efficacy, safety, and population pharmacokinetics of eravacycline for carbapenem-resistant organism infections in immunocompromised hosts: a multicenter prospective cohort study. Int J Antimicrob Agents 67(6):107795. https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107795","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"5811_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14787210.2024.2351552","volume":"22","author":"PY Huang","year":"2024","unstructured":"Huang PY, Hsu CK, Tang HJ, Lai CC (2024) Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications. Expert Rev Anti Infect Ther 22(6):387\u2013398. https:\/\/doi.org\/10.1080\/14787210.2024.2351552","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"10","key":"5811_CR11","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00565-25","volume":"13","author":"AJ Kunz Coyne","year":"2025","unstructured":"Kunz Coyne AJ, Alosaimy S, Lucas K, Morrisette T, Molina KC, DeKerlegand A, Schrack MR, Kang-Birken SL, Hobbs ALV, Agee J, Perkins NB, Biagi M, Pierce M, Truong J, Andrade J, Bouchard J, Gore T, King MA, Pullinger BM, Claeys KC, Herbin S, Cosimi R, Tart S, Veve MP, Jones BM, Rojas LM, Feehan AK, Zhao JJ, Witucki P, Rybak MJ (2025) Eravacycline use in immunocompromised patients: multicenter evaluation of timely versus late initiation on clinical outcomes. Microbiol Spectr 13(10):e0056525. https:\/\/doi.org\/10.1128\/spectrum.00565-25","journal-title":"Microbiol Spectr"},{"issue":"12","key":"5811_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ph18121827","volume":"18","author":"J Lei","year":"2025","unstructured":"Lei J, Lou Z, Jiang Y, Cui Y, Li S, Hu J, Jing Y, Yang J (2025) Disproportionality analysis of adverse events associated with IL-1 inhibitors in the FDA Adverse Event Reporting System (FAERS). Pharmaceuticals (Basel) 18(12):1827. https:\/\/doi.org\/10.3390\/ph18121827","journal-title":"Pharmaceuticals (Basel)"},{"key":"5811_CR13","doi-asserted-by":"publisher","first-page":"1746200","DOI":"10.3389\/fcimb.2026.1746200","volume":"16","author":"Y Li","year":"2026","unstructured":"Li Y, Yi Q, Zhou M, Lu M, Xu Y (2026) Real-world effectiveness and predictors of treatment failure for eravacycline in patients with Acinetobacter baumannii or Klebsiella pneumoniae infections: a multicenter retrospective analysis. Front Cell Infect Microbiol 16:1746200. https:\/\/doi.org\/10.3389\/fcimb.2026.1746200","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"5811_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70213","volume":"18","author":"X Liu","year":"2025","unstructured":"Liu X, Yuan X, Wen L, Tan X, Sui Q, Liu J (2025) Identification of risk factors and predictive indicators for tigecycline-associated hypofibrinogenemia. Clin Transl Sci 18(4):e70213. https:\/\/doi.org\/10.1111\/cts.70213. (PMID: 40181433)","journal-title":"Clin Transl Sci"},{"issue":"1","key":"5811_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1186\/s12879-025-11019-w","volume":"25","author":"H Ma","year":"2025","unstructured":"Ma H, Gong Z, Sun J, Chen L, SiRi G (2025) Development and validation of a risk prediction model for tigecycline-induced hypofibrinogenemia in septic patients: a retrospective cohort study. BMC Infect Dis 25(1):683. https:\/\/doi.org\/10.1186\/s12879-025-11019-w. (PMID: 40340646)","journal-title":"BMC Infect Dis"},{"issue":"12","key":"5811_CR16","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/sim.3320","volume":"31","author":"GN Nor\u00e9n","year":"2008","unstructured":"Nor\u00e9n GN, Sundberg R, Bate A, Edwards IR (2008) A statistical methodology for postmarketing surveillance: Bayesian confidence propagation neural network. Stat Med 31(12):1027\u20131038. https:\/\/doi.org\/10.1002\/sim.3320","journal-title":"Stat Med"},{"issue":"12","key":"5811_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01314-25","volume":"13","author":"K Patino","year":"2025","unstructured":"Patino K, Vathy R, Albrecht B, Suchindran S, Green SB (2025) Combating resistant pathogens: exploring the efficacy of eravacycline utilization in multidrug-resistant infections. Microbiol Spectr 13(12):e0131425. https:\/\/doi.org\/10.1128\/spectrum.01314-25","journal-title":"Microbiol Spectr"},{"key":"5811_CR18","doi-asserted-by":"publisher","first-page":"1585390","DOI":"10.3389\/fphar.2026.1585390","volume":"17","author":"Y Si","year":"2026","unstructured":"Si Y, Chen M, Zhang J, Jiang J, Zhang Y, Yu G, Guo N, Yan G, Leng B (2026) Incidence and characteristics of eravacycline-associated increase in serum bilirubin levels: a retrospective study. Front Pharmacol 17:1585390. https:\/\/doi.org\/10.3389\/fphar.2026.1585390","journal-title":"Front Pharmacol"},{"issue":"47","key":"5811_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000046044","volume":"104","author":"B Song","year":"2025","unstructured":"Song B, Zhang Y, Wang L, Hu J (2025) Comprehensive pharmacovigilance of phytoalkaloid chemotherapeutics: signal detection and time-to-onset analysis based on FAERS. Medicine (Baltimore) 104(47):e46044. https:\/\/doi.org\/10.1097\/MD.0000000000046044. (PMID: 41305724)","journal-title":"Medicine (Baltimore)"},{"key":"5811_CR20","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA (2024) Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis, ciae403. https:\/\/doi.org\/10.1093\/cid\/ciae403","DOI":"10.1093\/cid\/ciae403"},{"issue":"1","key":"5811_CR21","doi-asserted-by":"publisher","first-page":"17301","DOI":"10.1038\/s41598-025-02359-3","volume":"15","author":"F Tang","year":"2025","unstructured":"Tang F, He Y, Ou W, Yang N, Bai X (2025) A disproportionality analysis of adverse events associated with ertapenem using the FAERS database from 2004 to 2024. Sci Rep 15(1):17301. https:\/\/doi.org\/10.1038\/s41598-025-02359-3. (PMID: 40389541)","journal-title":"Sci Rep"},{"issue":"7","key":"5811_CR22","doi-asserted-by":"publisher","DOI":"10.1530\/EC-25-0305","volume":"14","author":"Z Wang","year":"2025","unstructured":"Wang Z, Wang Y, Wu T, Zhu H, Zhang L, Liao X (2025) Disproportionality analysis and risk factor assessment of drug-associated thyroid dysfunction adverse events: a study based on the FAERS database. Endocr Connect 14(7):e250305. https:\/\/doi.org\/10.1530\/EC-25-0305. (PMID: 40590710)","journal-title":"Endocr Connect"},{"issue":"3","key":"5811_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01287-25","volume":"70","author":"J Wang","year":"2026","unstructured":"Wang J, Zhu J, Wu W, Luo R, Liu Z, Tong Z, Sun T, Xu Y, Wu D (2026) Clinical outcomes and safety of eravacycline in hematology: a multicenter, real-world study. Antimicrob Agents Chemother 70(3):e0128725. https:\/\/doi.org\/10.1128\/aac.01287-25","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"5811_CR24","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s11096-025-01867-6","volume":"47","author":"X Wen","year":"2025","unstructured":"Wen X, Cai L, Gao A, Fu A, Guo D, Zhu M (2025) Pharmacovigilance analysis of drug-induced hypofibrinogenemia using the FDA Adverse Event Reporting System. Int J Clin Pharm 47(3):755\u2013766. https:\/\/doi.org\/10.1007\/s11096-025-01867-6. (PMID: 39888490)","journal-title":"Int J Clin Pharm"},{"key":"5811_CR25","doi-asserted-by":"publisher","first-page":"1693090","DOI":"10.3389\/fphar.2025.1693090","volume":"16","author":"Y Wu","year":"2025","unstructured":"Wu Y, Ke W, Li H (2025) A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod. Front Pharmacol 16:1693090. https:\/\/doi.org\/10.3389\/fphar.2025.1693090","journal-title":"Front Pharmacol"},{"issue":"8","key":"5811_CR26","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/14740338.2024.2392865","volume":"24","author":"CY Xiong","year":"2025","unstructured":"Xiong CY, Yang YM, Zhou Y, He TS, Luo XW, Wang J, Mao CX (2025) Systematic analysis of the adverse effects of commonly used clinical tetracycline drugs based on the FAERS database. Expert Opin Drug Saf 24(8):949\u2013957. https:\/\/doi.org\/10.1080\/14740338.2024.2392865. (PMID: 39140181)","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"5811_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms14010044","volume":"14","author":"Q Yi","year":"2025","unstructured":"Yi Q, Li Y, Zhou M, Jing R, Lu M, Xu Y (2025) Assessment of eravacycline antimicrobial susceptibility in China during the first year following regulatory approval (2023-2024): a real-world study. Microorganisms 14(1):44. https:\/\/doi.org\/10.3390\/microorganisms14010044","journal-title":"Microorganisms"},{"issue":"11","key":"5811_CR28","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1080\/14740338.2024.2393276","volume":"24","author":"X Zhang","year":"2025","unstructured":"Zhang X, Pan J, Zhang X, Yang Q, Li Z, Liu F (2025) Safety profiles of tetracycline-class drugs: a pharmacovigilance analysis of the FAERS database. Expert Opin Drug Saf 24(11):1341\u20131350. https:\/\/doi.org\/10.1080\/14740338.2024.2393276","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"5811_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0335449","volume":"20","author":"J Zou","year":"2025","unstructured":"Zou J, Zhan C, Feng Y, Liu Q, Peng G, Cai Z, Luo L, Zou J (2025) Drug-induced movement disorder: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2004 to 2024. PLoS One 20(10):e0335449. https:\/\/doi.org\/10.1371\/journal.pone.0335449","journal-title":"PLoS One"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05811-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05811-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05811-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:03:14Z","timestamp":1787230994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05811-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":29,"alternative-id":["5811"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05811-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"3 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study utilized data from the FDA Adverse Event Reporting System (FAERS), a publicly available, de-identified post-marketing surveillance database. All data are publicly accessible and contain no personally identifiable information. In accordance with applicable regulations, this study was exempt from institutional review board (IRB) approval and informed consent requirements. No human subjects were directly involved in this research.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study does not contain data from any individual person.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}